Related Experiment Video
Updated: Feb 10, 2026

A Standardized Procedure of Dressing Management for Toxic Epidermal Necrolysis
Published on: March 14, 2025
Toxic epidermal necrolysis associated with immune checkpoint inhibitors for bladder cancer: A case report
Yangyang Wang1, Lihua Liu2, Meiyun Li3
1Department of Pharmacy, Third Hospital of Changsha, Changsha 410000, China. w_yycsu@163.com.
Immune checkpoint inhibitors (ICIs) play a significant role in tumor treatment, but the immune-related adverse events (irAEs), which brings about have also attracted much attention. Among them, toxic epidermal necrolysis (TEN) is one of the most severe skin toxic reactions. This article reports a case of a bladder cancer patient who developed TEN after receiving ICIs treatment. The male patient was diagnosed with bladder cancer in November 2023. On April 29, 2024, he was admitted to the Third Hospital of Changsha for antitumor treatment. In May 2024, he developed immune-related myocarditis after treatment with toripalimab. On July 6, 2024, the patient switched to envafolimab treatment, and on July 16, he developed rashes and eventually progressed to TEN. After treatment with glucocorticoids and related symptomatic measures, the patient improved. TEN is a rare but serious irAE in ICIs treatment. Suspected patients should be intervened early, and patients who have already developed it should be actively treated, in order to enhance the understanding and management of TEN caused by ICIs treatment.
Immune checkpoint inhibitors (ICIs) play a significant role in tumor treatment, but the immune-related adverse events (irAEs), which brings about have also attracted much attention. Among them, toxic epidermal necrolysis (TEN) is one of the most severe skin toxic reactions. This article reports a case of a bladder cancer patient who developed TEN after receiving ICIs treatment. The male patient was diagnosed with bladder cancer in November 2023. On April 29, 2024, he was admitted to the Third Hospital of Changsha for antitumor treatment. In May 2024, he developed immune-related myocarditis after treatment with toripalimab. On July 6, 2024, the patient switched to envafolimab treatment, and on July 16, he developed rashes and eventually progressed to TEN. After treatment with glucocorticoids and related symptomatic measures, the patient improved. TEN is a rare but serious irAE in ICIs treatment. Suspected patients should be intervened early, and patients who have already developed it should be actively treated, in order to enhance the understanding and management of TEN caused by ICIs treatment.
Related Concept Videos
The Spindle Assembly Checkpoint
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
What is the Immune System?
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Data Reporting and Recording
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:

